Financials

  • Market Capitalization 2.59 B
  • Employee 221
  • Founded 1998
  • CEO Matt Kapusta
  • Website www.uniqure.com
  • Headquarter Netherlands
  • FIGI UNKNOWN
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-6.92
Price to sales ratio
85.48

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1713
VERA
Vera Therapeutics, Inc. - Class A Common Stock
41.50 USD-1.19%+3.03%+19.70%+39.54%2.98 B USD
1736
IRON
Disc Medicine, Inc. - Common Stock
75.98 USD-0.80%-2.71%+10.02%+31.02%2.90 B USD
1827
IMNM
Immunome, Inc. - Common Stock
22.80 USD-2.36%-5.00%+22.38%+166.36%2.58 B USD
1829
KOD
Kodiak Sciences Inc - Common Stock
41.10 USD-0.51%+9.34%+17.80%+675.47%2.57 B USD

Frequently asked questions about uniQure N.V. - Ordinary Shares

What is the uniQure N.V. - Ordinary Shares stock price today?

The current price of uniQure N.V. - Ordinary Shares (QURE) is 41.1. Over the past 24 hours, the stock has changed by -3.59%. Follow the QURE chart for real-time price dynamics.

What is the stock ticker of uniQure N.V. - Ordinary Shares?

uniQure N.V. - Ordinary Shares trades under the ticker QURE. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is uniQure N.V. - Ordinary Shares stock going up?

QURE has changed by -1.93% over the last week, +48.11% over the last month, and +181.51% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was uniQure N.V. - Ordinary Shares net income for the last quarter?

uniQure N.V. - Ordinary Shares reported net income of -53.53 M for the last quarter. The previous quarter showed -37.09 M, which means net income changed by -44.35%.

How many employees does uniQure N.V. - Ordinary Shares have?

As of the latest available data, uniQure N.V. - Ordinary Shares has 221 employees. Workforce size can provide additional context about the company's scale and operations.

What is uniQure N.V. - Ordinary Shares EBITDA?

uniQure N.V. - Ordinary Shares EBITDA is -50.24 M, and its EBITDA margin is -1 410.33%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy uniQure N.V. - Ordinary Shares stock?

You can buy uniQure N.V. - Ordinary Shares (QURE) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in uniQure N.V. - Ordinary Shares stock?

Investing in uniQure N.V. - Ordinary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the QURE chart and related analysis on metatrader.com as part of your research.

uniQure N.V. - Ordinary Shares

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

News